Donor Tregs suppress the good with the bad after allogeneic BMT

Leukemia Research

Volumn 35, Issue 12, 2011, Pages 1541-1542

  Choi, Sung ^a   Reddy, Pavan ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

BMT; GVHD; GVT; Tregs

Indexed keywords

GAMMA INTERFERON; TRANSCRIPTION FACTOR FOXP3;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN PRESENTING CELL; CANCER GROWTH; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DONOR LYMPHOCYTE INFUSION; EDITORIAL; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; FEMALE; GRAFT VS LEUKEMIA EFFECT; LEUKOCYTE TRANSFUSION; T-LYMPHOCYTES, REGULATORY;

EID: 80055101473     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.032     Document Type: Editorial

References (13)

1. Bleakley M., Riddell S.R. Molecules and mechanisms of the graft-versusleukaemia effect. Nat Rev Cancer 2004, 4(May (5)):371-380.
2. Bluestone J.A., Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3(March (3)):253-257.
3. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005, 22(March (3)):329-341.
4. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic selftolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
5. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005, 6(April (4)):338-344.
6. Shevach E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006, 25(August (2)):195-201.
7. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196(August (3)):389-399.
8. Edinger M., Hoffmann P., Ermann J., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9(September (9)):1144-1150.
9. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10(September (9)):942-949.
10. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006, 6(April (4)):295-307.
11. Sakaguchi S., Powrie F. Emerging challenges in regulatory T cell function and biology. Science 2007, 317(August (5838)):627-629.
12. Reddy P., Maeda Y., Liu C., Krijanovski O.I., Korngold R., Ferrara J.L. A crucial role for antigen-presenting cells and alloantigen expression in graft-versusleukemia responses. Nat Med 2005, 11(11):1244-1249.
13. Choi M.-S., Lim J.-Y., Cho B.-S., et al. The role of regulatory T cells during the attenuation of graft-versus-leukemia activity following donor leukocyte infusion in mice. Leuk Res 2011, 35:1549-1556.